RSS Feeds
GM-CSF Treatment and Hypokalemia
- P. Viens, MD;
- A. Thyss, MD;
- G. Garnier, MD;
- P. Ayela, MD;
- M. Lagrange, MD; and
- M. Schneider, MD
Excerpt
To the Editor: Granulocyte-macrophage colony-stimulating factor (GM-CSF) is currently proposed as a means for accelerating hematopoietic recovery after aplasia-inducing chemotherapy (1, 2) and as an agent for treating myelodysplasias (3). The various side effects described are rarely of a metabolic nature. We report a case of severe acute hypokalemia in a patient treated with GM-GSF.
A 79-year-old woman was hospitalized for GM-CSF treatment (GM-CSF obtained from Cho-Cell, Sandoz Pharmaceuticals, Basel, Switzerland) because of refractory anemia with excess blast cells as defined by the FAB (French American British Cooperative) requiring erythrocyte transfusions every 4 weeks (randomized study of the Leukemia group
This 100-word excerpt has been provided in the absence of an abstract.
